News
Inhaled Therapies for IPF – an update
In a recent blog we reflected on key presentations at the ERS relating to pulmonary fibrosis, including the promise shown by the orally-delivered preferential PDE4B
Reflections from ERS 2025
From a Pulmonary fibrosis perspective, the ERS meeting in Amsterdam (27 September to 1 October, 2025) provided a combination of hope, challenge and satisfaction for
Society for Medicines Research (SMR) Meeting on Women’s Health
Darcey Black, Translational Science Director at TherapeutAix, will be attending and co-chairing a session at the forthcoming SMR Meeting on Women’s Health, taking place at
Biking for Action Medical Research
Our co-founder and Director of Translational, Darcey Black, is planning to take part in the BiotechBikers “Catalyst” Charity Event, a 250-mile cycle ride from London
TherapeutAix Roundup: 2024
As another year comes to a close, we reflect on 12 months filled with innovation and collaboration at TherapeutAix. From kickstarting the year with strategic
Exploring the Potential of Inhalation Therapies for IPF: Lessons from Asthma
A few weeks ago, our updated review on the state of drug development in Idiopathic Pulmonary Fibrosis (IPF) was published in Drug Discovery Today. This update
The Evolving Landscape of IPF Drug Discovery and Development
Idiopathic Pulmonary Fibrosis (IPF) remains one of the most challenging respiratory diseases to treat, characterized by progressive lung scarring and severely unpredictable disease progression. Despite